

# Eptacog Beta in Glanzmann's (HeT\_LFB-Strength-Study\_FID531)

NCT07136857

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Emory University
Enrollment	6 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- Adult or Pediatric persons with inherited Glanzmann thrombasthenia (see diagnostic criteria below)
- Severe bleeding phenotype
- Adequate hepatic function
- Adequate renal function
- Adults subject (≥18 years of age) or caregiver (parent or legally authorized representative) for minor subjects, subjects with cognitive impairment, or subjects with impaired decision-making capacity have provided written informed consent, and the participant has given consent/assent (if applicable)

... and 1 more (see full listing online)

### Exclusion (11)

- Thrombocytopenia (platelet count  $< 100k$ )
- Acquired Glanzmann thrombasthenia secondary to autoimmune disease, malignancy, or medication
- Inherited or acquired bleeding diathesis other than Glanzmann thrombasthenia
- Have a history of venous or arterial thrombotic event within 2 years of study enrollment
- Active malignancy

... and 6 more (see full listing online)

## Locations (1 total)

---

Arthur M. Blank Hospital | Children's Healthcare of Atlanta, Atlanta, Georgia, United States